However, Gould believes that AbbVie’s differentiated earnings per share growth remains robust, driven by its other key products such as Skyrizi and Rinvoq. Gould anticipates that AbbVie’s commercial ...

If AbbVie is successful in bringing breakthrough drugs to market, it may be able to drive long-term growth while decreasing ...

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...

AbbVie’s Humira missed Wall Street’s expectations in the third quarter but Skyrizi and Rinvoq’s continuing outperformance ...

However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a ...

Argus upgraded AbbVie (ABBV) to Buy from Hold with a $220 price target Two of the company’s key immunology products, Skyrizi and Rinvoq, have succeeded Humira as growth engines, with the former having ...

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its ...

This morning, pharma major AbbVie and fellow USA-based EvolveImmune Therapeutics announced the signing of a collaboration and ...

AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies ... Packaging The company didn't disclose how many toys were affected or if it was recalling any products. Tencent to Invest $500 Million in ...

EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with ...

AbbVie cautions that these forward-looking statements ... strong growth well into the next decade. Several other key products also delivered double-digit sales growth, including Venclexta, Vraylar ...